arrow
R

Rebeca Bailén

Hospital General Universitario Gregorio Marañon
H指数:20
被引数:1,499

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Plasma ST2 and Angiopoietin-2, but Not Hyaluronan, Retain Discriminatory Performance for Sinusoidal Obstruction Syndrome after Allogeneic HSCT with High-Dose Post-Transplant Cyclophosphamide

血浆ST2和血管生成素-2,而非透明质酸,在异基因HSCT联合高剂量移植后环磷酰胺治疗后仍保持对窦状阻塞性综合征的鉴别诊断性能

2026-10-230
PRE
Spanish Real-World Experience with Belumosudil for Chronic Graft-versus-Host Disease after 2 or More Prior Lines of Therapy

西班牙真实世界经验:Belumosudil在2种或更多先前治疗方案后的慢性移植物抗宿主病中的应用

2026-03-050
PRE
ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling

CD19 car-t治疗中的ICANS风险模型: 来自血清和CSF细胞因子分析的见解

2025-07-240
OAAI
Chimeric antigen receptor T-cell therapy outcomes in T cell/histiocyte-rich large B-cell lymphoma and subsequent treatment strategies after disease progression: A GELTAMO/GETH study

嵌合抗原受体T细胞疗法在T细胞/组织细胞丰富的大B细胞淋巴瘤中的疗效及疾病进展后的后续治疗策略:一项GELTAMO/GETH研究

2025-02-040
OAAI
ASTCT Consensus Recommendations on Testing and Treatment of Patients with Donor-specific Anti-HLA Antibodies
2024-12-013
PRE
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma
2024-11-070
OAAI
Outcomes of Allogeneic Transplantation with Clofarabine and Post-Transplant Cyclophosphamide-Based Conditioning in Patients with Very High-Risk Acute Myeloid Leukemia

异基因移植联合氯法拉滨和基于移植后环磷酰胺的预处理在极高风险急性髓系白血病患者中的疗效

BLOOD
IF23.1
2024-11-050
PRE
BONE Marrow Chimerism and Measurable Residual Disease Analysis Interplay: Impact on Prognosis of ACUTE Myeloid Leukemia Undergoing STEM Celltransplatation

骨髓嵌合与可测量残留病灶分析相互作用:对接受干细胞移植的急性髓系白血病预后的影响

BLOOD
IF23.1
2024-11-050
PRE
Real-World Experience with Isavuconazole in Allogeneic Stem Cell Transplantation in Spain

在西班牙异基因干细胞移植中使用Isavuconazole的真实世界经验

2024-10-010
PRE
Anti-CD19 CAR-T Cell Therapy in Elderly Patients: Multicentric Real-World Experience from GETH-TC/GELTAMO

老年患者的Anti-CD19 car-t细胞治疗: 来自GETH-TC/GELTAMO的多中心真实世界经验

2024-10-012
PRE
Characterization of Chronic Graft-versus-host Disease After Haploidentical Stem Cell Transplantation With Posttransplant Cyclophosphamide: A Study on Behalf of GETH-TC
2024-09-240
PRE
Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-Transplantation Cyclophosphamide: A Study on Behalf of the Spanish Hematopoietic Stem Cell Transplantation and Cellular (GETH)
2024-09-011
PRE
Use of Eltrombopag to Improve Thrombocytopenia and Tranfusion Requirement in Anti-CD19 CAR-T Cell-Treated Patients
2024-08-282
OAAI
Identification of predictive models including polymorphisms in cytokines genes and clinical variables associated with post-transplant complications after identical HLA-allogeneic stem cell transplantation
2024-08-231
OAAI
Efficacy and safety of bendamustine-containing bridging therapy in R/R LBCL patients receiving CD19 CAR T-cells
2024-06-260
OAAI
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey (vol 52, pg 1125, 2024)

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查结果 (第52卷,1125页,2024页)

2024-05-210
OAAI
Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry

地塞米松治疗新型冠状病毒肺炎与血液系统恶性肿瘤患者的死亡率增加有关: EPICOVIDEHA注册表的结果

2024-04-042
OAAI
Digital PCR Improves Sensitivity and Quanti fi cation in Monitoring CAR-T Cells in B Cell Lymphoma Patients
2024-03-014
OAAI
Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey

重症新型冠状病毒肺炎和血液系统恶性肿瘤患者的ICU需求和结局: EPICOVIDEHA调查的结果

2024-02-224
OAAI